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INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is the most
frequent and life-threatening infection in patients
with liver cirrhosis requiring prompt recognition
and treatment. It is defined by the presence of >250
polymorphonuclear cells (PMN)/mm3 in ascites in
the absence of an intra-abdominal source of infec-
tion or malignancy. In this review we discuss the
current opinions reflected by recent guidelines
(American Association for the Study of Liver
Diseases, European Association for the Study of the
Liver, Deutsche Gesellschaft für Verdauungs- und
Stoffwechselkrankheiten),1e4 with particular focus
on controversial issues as well as open questions
that need to be addressed in the future. First,
diagnostic criteria and tools available for rapid and
accurate diagnosis are reviewed. Second, since
prophylaxis is of crucial relevance when trying to
improve survival, we discuss who should be
treated, when, how and for how long to prevent
episodes of SBP. Identification of risk factors and
individualisation of timing and selection of
prophylactic measures are the key to success
without major development of resistant bacteria.
Finally, effective therapy is essential since treat-
ment failure is associated with poor outcome. Since
the emergence and spread of drug-resistant bacteria
has accelerated, criteria for the choice of antibiotic
regimen in the individual patient are pivotal for
optimising therapy.
EPIDEMIOLOGY AND PROGNOSIS OF SBP
SBP is the most frequent bacterial infection in
cirrhosis, accounting for 10e30% of all reported
bacterial infections in hospitalised patients.5e7 In
outpatients without symptoms the prevalence is
low (3.5%8 or lower9 10), but the prevalence
increases in the nosocomial setting, ranging from
8% to 36%.11 12 Bacterascites, defined as positive
culture results but no increase in the PMN count in
the ascitic fluid, occurs with a prevalence of 2e3%
in outpatients8e10 and in up to 11% in hospitalised
patients.11 13 In-hospital mortality for the first
episode of SBP ranges from 10% to 50%, depending
on various risk factors.7 14e18 One-year mortality
after a first episode of SBP has been reported to be
31% and 93%.8 17 19e21 In fact, the occurrence of
SBP or other severe bacterial infections markedly
worsens the prognosis in patients with cirrhosis
and it has been proposed that a new prognostic
stage of cirrhosis not reflected in current staging
systems should be defined, the so-called ‘critically
ill cirrhotic’.22 Patients at this late stage have to be
evaluated for the possibility of liver trans-
plantation. Predictive factors reported for a poor
prognosis in various cohorts of patients with SBP
are summarised in figure 1 and include age,16 20
Child score,18 20 23 intensive care,16 18 nosocomial
origin,18 24 hepatic encephalopathy,25 elevated
serum creatinine and bilirubin,26 lack of infection
resolution/need to escalate treatment and culture
positivity27e29 as well as the presence of bacter-
aemia30 and CARD15/NOD2 variants as a genetic
risk factor.31 It is important to stress in this context
that the only factors that are modifiable in this
scenario are timely diagnosis and effective first-line
treatment.
Bacterial translocation (BT) and pathophysiology
Bacterial translocation (BT) is the most common
cause of SBP.32 33 However, particularly in nosoco-
mial SBP, other sources such as transient bacter-
aemia due to invasive procedures can lead to SBP.
Limited BT to mesenteric lymph nodes (MLN) is
a physiological phenomenon, whereas any increase
in the rate and severity of BT may be deleterious
for the patient and thus should be termed ‘patho-
logical BT’. Only a few intestinal bacteria are
able to translocate into MLN, including Escherichia
coli, Klebsiella pneumoniae and other Enter-
obacteriaceae.34 Interestingly, these species most
frequently cause SBP, and DNA sequencing studies
reveal genotypic identity of bacteria in MLN and
ascites in the vast majority of cases.35 36 This
suggests that pathological BT is the underlying
cause and source of SBP in cirrhosis and supports
the view that the route of pathological BT leading
to SBP is largely lymphatic. Three factors have been
implicated in the development of pathological BT
in liver cirrhosis32: (1) alterations in gut microbiota;
(2) increased intestinal permeability; and (3)
impaired immunity.
Microbiota
Liver cirrhosis is associated with distinct changes in
faecal microbial composition37 38 including an
increased prevalence of potentially pathogenic
bacteria such as Enterobacteriaceae. Moreover,
small intestinal bacterial overgrowth (SIBO),
defined as >105 colony forming units/ml jejunal
aspirate and/or colonic-type species, is frequently
present in advanced stages of liver cirrhosis and
has been linked with pathological BT, SBP and
endotoxinaemia.39e41 In cirrhosis, factors
promoting these changes may include deficiencies
in paneth cell defensins,41a reduced intestinal
motility, decreased pancreatobiliary secretions and
portal-hypertensive enteropathy. In experimental
cirrhosis, in the absence of SIBO, BT occurs rarely
(0e11%) and at rates comparable to healthy
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conditions. However, BT does not occur in up to
half of the animals with SIBO and, thus, SIBO is
necessary but not sufficient for BT to occur.
Intestinal permeability
Cirrhosis is associated with structural and func-
tional alterations in the intestinal mucosa that
increase permeability to bacteria and bacterial
products. In particular, changes in enterocyte
mitochondrial function and increased oxidative
stress of the intestinal mucosa have been
identified.42 43
Host defence
For translocation to become clinically significantd
that is, for it to lead to SBP or bacteraemiada
failure of local and systemic immune defences
appears to be the most important prerequisite (see
below).
Local ascitic-peritoneal host defence in peritonitis
The peritoneal cavity probably has the most severe
lack of host defence compared with other
compartments in decompensated cirrhosis. In fact,
ascites per se may be considered a risk factor for the
development of peritonitis. In healthy conditions,
peritoneal host defence mechanisms are very effi-
cient and intraperitoneal injection of various
numbers of single organisms does not cause peri-
tonitis unless adjuvant substances or ascites are
present.44 In cirrhosis, deficiencies in local defence
mechanisms against bacteria, including dysfunc-
tion of cellular and humoral immunity, limit
peritoneal bacterial clearance.
Since the absolute number of PMN per mm3
ascitic fluid defines SBP, the mechanisms of
chemotaxis mediating PMN influx into the perito-
neal cavity are important. The degree of PMN
migration and accumulation in the peritoneal
cavity combating invading bacteria depends on
a number of factors. Resident macrophages are the
first to phagocytose bacteria, they further help to
attract PMN by release of chemotactic factors and
activate complement. For instance, monocyte
chemotactic protein 1 is one of the most potent
chemokines, and a functional polymorphism has
been proposed as a risk factor for SBP in alcoholic
cirrhosis.45 A chemotactic gradient is necessary to
achieve appropriate neutrophil recruitment into the
peritoneal cavity. In fact, PMN chemoattractants
such as zymosan are very effective in preventing
the death of animals with E coli-induced peritonitis
when administered locally but not systemically.46
Unfortunately, little is known about the influx,
efflux and kinetics of neutrophils in ascitic fluid in
cirrhosis and its dependency on type, extent and
duration of bacterial stimulus as well as host
factors.
Besides influx of PMN, bacterial clearance is
determined by the overall killing capacity which is
dependent on opsonisation, burst activity and
inflammatory response. A marked reduction in
opsonic and bactericidial activity is well-known in
cirrhosis. In particular, low C3 levels in cirrhotic
ascites correlate strongly with opsonic activity47
and have been shown to predispose to SBP.48
However, the total protein content aslo mirrors
opsonic activity and has been shown to be predic-
tive of the development of SBP.49 At a protein level
of >1.5 g/dl ascitic fluid, the incidence rates of SBP
have been consistently reported to be lower than
1%. In contrast, at protein levels <1.5 g/dl ascitic
fluid, the risk of SBP increases, parallelling the
decrease in protein content and reaching incidence
rates of 27e41% at levels <1.0 g/dl.19 50 51 Other
factors that may contribute but have not been
addressed thoroughly include compartmentalisa-
tion via activation of coagulatory systems or the
omentum (called the ‘abdominal policeman’) and
visceral fat. The latter is a relevant source of
adipokines known to modulate the inflammatory
response. In fact, significant levels of, for example,
adiponectin, visfatin and resistin are observed in
ascites and the latter is increased in the presence
of SBP.52
Liver dysfunction and systemic risk factors
Cirrhosis is accompanied by deficits in innate and
adaptive intrahepatic, intestinal and systemic
immunity. Patients with cirrhosis with decreased
reticuloendothelial system (RES) activity develop
SBP at a higher rate than those with close to
normal RES activity.23 Accordingly, markers of
advanced liver dysfunction have been identified as
independent risk factors for a first episode of SBP. A
bilirubin level of >3.2 mg/dl and platelet count of
<98 000/mm3 significantly increase the likelihood
of SBP,53 and each model for end-stage liver disease
(MELD) point increases the risk of SBP by about
11%.54 However, circulating mononuclear cells also
present with alterations in Toll-like receptor
(TLR)55 and HLA expression56 57 as well as reduced
Figure 1 Spontanous bacterial peritonitis (SBP)-associated mortality. Reported risk
factors for poor prognosis in SBP are categorised into fixed or modifiable factors as well
as host and bacterial factors, respectively. The most relevant for survival is resolution of
infection which is best influenced by effective first-line therapy since other factors are
not modifiable.
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chemotactic, opsonic, phagocytic and killing
capacity.58 59 Furthermore, genetic variants influ-
encing host defence mechanisms such as CARD15/
NOD231 60 and TLR261 have been reported to be
associated with an enhanced probability of
acquiring SBP. TLR2 polymorphisms and NOD2
variants seem to represent supplementary risk
factors since the simultaneous presence of both
unfavourable polymorphisms markedly increases
the risk of SBP.61 This underlines the known
interaction of NOD2 and TLRs, in particular the
modulation of TLR2-dependent cytokine responses
by NOD2.62
Medication can also affect the chances of devel-
oping SBP. The use of proton pump inhibitors (PPI)
has been proposed to facilitate SIBO and thus to
contribute to pathological BT. In fact, retrospective
caseecontrol studies reveal a potential association
between the use of PPI and development of
SBP.63 64 Considering the frequently inadequate
overuse of PPI in patients with cirrhosis, we
therefore recommend restricting their use to indi-
cations of proven benefit. In contrast, non-selective
b-blockers (NSBB) may prevent SBP.65 66 It is
tempting to speculate that this benefit relates to an
improvement in chemotaxis, proinflammatory
cytokine release and killing capacity reported for
b-adrenergic antagonists in various experimental
settings.67 68 Since the sympathetic nervous system
affects PMN chemotaxis, the question arises as to
how treatment with NSBB affects the validity of
diagnosing SBP based on PMN count in the ascitic
fluid.
DIAGNOSIS OF SBP
Symptoms and signs are frequently absent in
patients with SBP,69 so a diagnostic paracentesis
should be performed in all patients with ascites
admitted to hospital regardless of whether or not
there is clinical suspicion. Diagnosis should be
prompt and treatment must not be delayed until
the microbiology results are available. Thus, in all
the available guidelines, diagnosis is based on a fixed
defined cut-off PMN count in the ascitic fluid.1e4 In
patients with haemorrhagic ascites (ie, red blood
cell count >10 000/mm3), subtraction of one PMN
per 250 red blood cells should be made to adjust for
the presence of blood in ascites. Owing to the short
lifespan of PMN, their ascitic count is independent
of diuretics and/or other modulations of ascites
volume. In contrast, lymphocytes which have
a long lifespan increase in concentration during
diuresis.70 Moreover, differential diagnoses of
predominant lymphocytosis in ascitic fluid include
tuberculous peritonitis, neoplasms, congestive
heart failure, pancreatitis and myxedema, but not
usually SBP. PMN are therefore used to define SBP,
and the greatest sensitivity is reached at a cut-off
value of 250 PMN/mm3, although the best speci-
ficity has been reported with a cut-off of 500 PMN/
mm3.71e74 However, since it is important not to
miss a case of SBP, the most sensitive cut-off value
is used. Nonetheless, this upper limit has been set
quite arbitrarily since it was tested in the setting of
culture-positive peritonitis. Thus, the range of
PMN in truly non-infected ascitesdthat is, the
ascitic PMN count that is clinically relevant for
the patientdis not known. Moreover, SBP caused
by Gram-positive cocci has been reported
frequently to have a PMN count below the
threshold of 250/mm3.75 Interestingly, bactDNA
from Gram-negative bacteria in ascitic fluid is
associated with a higher ascitic PMN count than
bactDNA from Gram-positive bacteria,76 under-
scoring the differences in stimulatory capacity for
PMN migration depending on the type of bacteria.
Microscopy versus automated cell counter
Ascitic PMN cell counts can be determined either
by a traditional haematological method using
a light microscope and a manual counting chamber
or by automated cell counters.77e79 Current
guidelines either do not state specifically the
method to be used2 4 or recommend microscopy as
the preferred method.1 However, microscopic eval-
uation is labour-intensive, time-consuming and has
high intraoperator and interoperator variability. In
contrast, automated cell counters, if available, are
easily accessible in emergencies and provide results
within minutes at low cost. Their use has
recently been validated in patients with cirrhotic
ascites,77 79 revealing sufficient sensitivity for
detection of SBP, and thus should be recommended.
However, it is important to stress that not all
automated cell counters fulfil the quality criteria.
These include sufficient functional sensitivity, test
precision and accuracy, particularly for automated
leucocyte counts in ascites even with low cell
concentrations (eg, XE-5000 (Sysmex, Mundelein,
IL, USA), Advia 120 (Erlangen, Germany), Iris
iQ200 (Chatsworth, CA, USA), CellDyn-4000
(Wiesbaden, Germany)).
None of the recent guidelines recommends the
use of reagent test strips to assess leucocyte esterase
activity of activated PMNs for the diagnosis of SBP
owing to unacceptable rates of false negative
results.80 However, most of the strips used to date
have been developed for urinary tract infections
with a threshold of >50 PMN/mm3.81 Recently,
a reagent strip test has been calibrated for ascitic
fluid with a cut-off of 250 PMN/mm3.82 Validity
scores achievable were reported to be 100% sensi-
tivity and 100% negative predictive value.
However, this needs to be confirmed in large
multicentre trials and, furthermore, the test was
not interpretable in bloody, chylous or bilious
ascitic fluid.
Bacterial DNA detection and culture techniques
Detection of bacterial DNA (bactDNA) using
various approaches has recently been proposed in
the ascitic fluid of patients with cirrhosis.83e85 The
advantage of such a system would be the imme-
diate identification of the causative bacteria, thus
enabling more accurately targeted antibiotic treat-
ment. BactDNA is found in the ascitic fluid of
about 40% of patients with cirrhosis, being derived
mainly from Gram-negative bacteria.84 85 However,
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detection of bactDNA in ascites or serum was not
associated with an enhanced incidence of SBP and
does not appear to predict the development of
bacterial infections.86
Culture techniques
Gram staining of peritoneal fluid is rarely helpful87
and is not recommended. In contrast, culture is the
recommended procedure. Although only a few
species and genera are found to cause SBP, more
than 70 different microbial species have been
isolated from the ascitic fluid of patients with
bacteriologically-confirmed SBP.88 Classical culture
techniques fail to grow bacteria in up to 65% of
neutrocytic ascites. Bedside inoculation of ascites
into blood culture bottles has been shown to
increase the sensitivity to nearly 80%.89e91 In this
regard, non-radiometric (eg, colorimetric BacTec)
systems in particular have improved the time to
diagnosis since they are faster than conventional
blood culture bottles.89 Handling processes influ-
ence culture results and delay in transport increases
false negative results.92 Separate and simultaneous
blood cultures should be collected since 30e58% of
SBP cases are associated with bacteraemia.30 93
Other markers of inflammation and secondary
peritonitis
Other markers found to be indicative of SBP include
ascitic pH, lactate dehydrogenase, lactate (and
corresponding arterialeascitic gradients), but none
of these is sufficiently predictive or discriminative
and may be increased in malignancy-related
ascites.72 74 94 95 Proteins such as granulocyte
elastase96 and lactoferrin97 released by PMN upon
activation have likewise been shown to be
increased in SBP. Lactoferrin was reported to give
rates of sensitivity and specificity of 95.5% and
97%, respectively, using a cut-off value of 242 ng/
ml and to decrease to below the cut-off value in
patients responding to treatment.97 However,
because of the small number of SBP cases in this
investigation, confirmation is required in multi-
centre trials including assessment of its accuracy in
haemorrhagic and coexisting malignant ascites.
Differentiation of SBP from secondary peritonitis
due to perforation or inflammation of an intra-
abdominal organ is clinically very relevant as the
associated mortality is exceedingly high.98 In fact,
all patients with perforated secondary peritonitis
not undergoing timely surgery have been reported
to die during hospitalisation and, thus, delayed
diagnostic investigation is fatal. However, the
proposed criteria to suspect secondary peritonitis
(eg, inadequate response to therapy, multiple
organisms)1 3 are identified too late and therefore
rapid and accurate ‘chemical’ parameters available
at the time of paracentesis are needed. Parameters
proposed by Runyon et al are neutrocytic ascites
with at least two of the following three criteria:
ascitic fluid total protein >1 g/dl (in contrast to
SBP), glucose <50 mg/dl (due to bacterial glucose
utilisation) or lactate dehydrogenase >225 mU/
ml.99 The sensitivity of these criteria can be less
than 68%98 99 and thus can be optimised. In addi-
tion, Wu et al reported that ascitic fluid with either
alkaline phosphatase >240 U/l or carcinoem-
bryonic antigen >5 ng/ml in 80% of cases reflects
peritonitis of secondary origin.100 Although no data
are available on the diagnostic accuracy of the
combined criteria (ie, those of either Wu et al or
Runyon et al), they are likely to improve sensitivity
and should be tested prospectively. In the
meantime, we strongly recommend performing an
abdominal CT scan as soon as any of these features
are present.101
TREATMENT OF SBP
Treatment has to be started immediately after
diagnosis of SBP and therefore is empirical since
culture results are not available at this time point.
The strain of bacteria causing SBP mainly depends
on the site of acquisition. However, none of the
international guidelines to date differentiates
Box 1
Key messages established unequivocally
< Clinical judgement does not rule out SBP and
thus a diagnostic paracentesis should be
performed in all patients with cirrhosis and
ascites at hospital admission and/or in case of
gastrointestinal bleeding, shock signs of inflam-
mation, worsening of liver/renal function or
hepatic encephalopathy.
< SBP is defined by >250 PMN/mm3 and
bacterascites by positive culture results of
ascitic fluid in the absence of PMN >250/mm3.
< Ascitic fluid culture is important to guide
antibiotic therapy and should be performed in
all patients before starting antibiotic treatment
by inoculation of ascites into blood culture
bottles at the patient’s bedside.
Controversial but proposed
< PMN count in ascitic fluid can be determined
either by microscope OR appropriate automated
cell counters. Reagent strips currently cannot be
recommended for rapid diagnosis of SBP but
ascites-calibrated sticks may become available.
< Bacterial DNA is not useful in detecting or
predicting the occurrence of SBP.
Questions to be addressed in the future
< Are there potential differences in the detection
of SBP dependent on the use of b-blockers and
the type of causative bacteria (Gram-positive vs
Gram-negative)?
< Is the fixed cut-off PMN count used for defining
SBP the best choice, or is the chemotactic
capacity of each individual patient relevant?
< Which parameters are sufficiently sensitive to
guide rapid imaging for detection of secondary
peritonitis?
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between nosocomial and community-acquired SBP
with regard to the type of antibiotic regimen to use.
This may be deleterious since nosocomial infections
are associated with high rates of bacterial multi-
resistance and mortality (J G Acevedo, personal
communication, 2009).24 102 Patients with cirrhosis
are also at increased risk of healthcare-associated
infections,103 but studies are needed to determine
the associated risk for multiresistant bacteria
causing SBP.
Community-acquired SBP: complicated and
uncomplicated cases
Historically, Gram-negative bacteriadalmost
exclusively Enterobacteriaceaedhave been isolated
in the overwhelming majority of SBP cases. More
recently, several studies have found an increasing
rate of infections with Gram-positive bacteria and
resistant microorganisms (J G Acevedo, personal
communication, 2009).24 29 102 However, in
patients with no previous hospitalisation and no
prior antibiotic treatment, the causative bacteria
still usually belong to the easily treatable Enter-
obacteriaceae family of bacteria. Several antibiotics
have been recommended for the initial treatment of
SBP in these cases including cefotaxime or other
third-generation cephalosporins, amoxicillin-clav-
ulanic acid or quinolones. Although earlier trials
have shown comparable efficacy of intravenous
amoxicillin/clavulanic acid (1/0.2 g every 8 h) and
intravenous cefotaxime in the treatment of SBP,
recent increases in resistance to aminopenicillin/
b-lactamase inhibitors104 may limit their useful-
ness. In patients presenting without complicating
factors that may worsen therapeutic efficacy, oral
treatment with quinolones appears sufficient in
countries with a relatively low rate of quinolone-
resistant strains of E coli. Possible complicating
factors include shock, ileus, gastrointestinal
bleeding, severe hepatic encephalopathy or renal
dysfunction (serum creatinine >3 mg/dl).105
Nosocomial SBP: treatment failure, risk factors and
recommendations
In nosocomial SBP, use of the antibiotics recom-
mended above (third-generation cephalosporins,
amoxicillin/clavulanic acid or quinolones) has
recently led to disappointing and unacceptably low
rates of resolution (J G Acevedo, personal commu-
nication, 2009).29 106 Resistance to third-generation
cephalosporins and quinolones has been reported to
increase continuously and to reach levels of
23e44% and 38e50%, respectively, in some insti-
tutions and countries (J G Acevedo, personal
communication, 2009).24 29 106 107 In addition, the
incidence of extended-spectrum b-lactamase
(ESBL)-producing bacteria as well as multiresistant
Gram-positive bacteria such as Enterococcus faecium
or methicillin-resistant Staphylococcus aureus
(MRSA) causing nosocomial SBP is alarming (table
1). MRSA has been found in 24e27% of cases of
SBP, with detection of S aureus in ascites several
years ago.75 112 Fortunately, the numbers are
decreasing in most European countries.113 In
contrast, the Study for Monitoring Antimicrobial
Resistance Trends reported that hospital-acquired
ESBL-positive E coli in any intra-abdominal infec-
tion have increased in Europe from 4.3% in 2002 to
11.8% in 2008.114 115 ESBLs cause resistance to
various types of newer b-lactam antibiotics
including third-generation cephalosporins and
monobactams and, in addition, frequently also
carry genes encoding resistance even to other anti-
biotics including quinolones, tetracyclines and
antifolates.116 ESBL resistance genes/plasmids
rapidly spread around the world, with foreign
travel being associated with intestinal colonisation
rates as high as 32% in Asia (and 88% specifically in
India).117 118 Moreover, colonisation of these resis-
tant organisms persists in a large proportion of
patients for many months117 and any antibiotic
treatment causes selective pressure, accelerating the
clinical relevance of these bacteria.119 For SBP,
ESBL-positive strains are not yet as frequent as in
Asia but have been reported to cause up to 22% of
nosocomial infections in Spain (J Fernandez,
personal communication, 2010). However, among
European countries and even among institutions in
the same country, there are wide differences in
resistance rates. For instance, for E coli isolates,
susceptibility rates of ciprofloxacin or ampicillin/
sulbactam are 90% and 65%, respectively, in
Estonia but are 52% and 32% in Turkey.114
The clinical relevance of these numbers is
reflected in the associated morbidity, healthcare-
associated costs and mortality. In a number of
independent investigations, in-hospital mortality
and/or 30-day mortality have been shown to be
increased in nosocomial SBP caused by multi-
resistant bacteria compared with common
bacteria (J G Acevedo, personal communication,
2009).75 102 106 111 In some series, most patients
with SBP due to multiresistant bacteria died within
the first 5 days after the diagnosis of SBP was made
and, indeed, none of the patients with persistent
infection survived.29 A meta-analysis of recently
published data found a four times increased risk of
mortality associated with bacterial resistance in
SBP (figure 2). Nosocomial SBP due to ESBL strains
or to multiresistant bacteria is often associated
with a failure of first-line empirical antibiotic
treatment.29 102 109 Indeed, the need for escalation
of treatment associated with poor survival is
predictive of in-hospital mortality24 29 and there-
fore must be avoided. The use of carbapenems and
glycopeptides would be safest and easiest since no
resistance has so far been reported in cases of SBP,
but this is not practical and the choice of antibi-
otics needs to be stratified for parameters defining
the risk of resistant bacteria. This includes host
factors as well as validated knowledge of the
resistance profile of bacteria acting in the setting in
which the patient is diagnosed and treated.
Reported independent risk factors for bacterial
multiresistance are previous hospitalisation
(particularly within 3 months and intensive care
treatment) and prior prophylactic or therapeutic
antibiotic treatment (figure 3).24 29 120 121 It is
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therefore suggested that, in patients with cirrhosis
who develop nosocomial SBP and present with such
risk factors, a more effective first-line empirical
antibiotic therapy with a broader spectrum should
be used, namely carbapenems. However, this
regimen should be de-escalated as soon as possible if
microbiological results reveal non-resistant easily
treatable causative microorganisms. This minimises
resistance selection pressure on the carbapenems
and underlines the paramount importance of
obtaining appropriate microbiological cultures.
Global susceptibility statistics from intra-abdom-
inal infections show that the susceptibilities of
Gram-negative isolates to the carbapenems have
remained stable over the past years, with E coli and
K pneumoniae isolates, including ESBL-positive
isolates, being 98e100% susceptible.122 Imple-
menting carbapenems as first-line treatment in
patients with nosocomial SBP with risk factors for
multiresistant bacteria can therefore save lives. This
has also been recommended in recent guidelines on
the treatment of sepsis,123 aiming at rapid initia-
tion of an antibiotic regimen likely to cover all
expected causative microorganisms. The same
should be even more true for patients with
decompensated cirrhosis who have an enhanced
proinflammatory response to bacterial stimuli124
and exhibit an increased susceptibility for any
vasodilatory stimulus due to the already highly
hyperdynamic splanchnic circulation.125
Treatment of bacterascites
It is controversial whether culture-positive results
in the absence of an increased PMN count in the
ascitic fluid require immediate initiation of antibi-
otic therapy. Some guidelines recommend antibi-
otic treatment only in patients with signs of
infection or inflammation.4 Otherwise, a follow-up
paracentesis should establish whether SBP is
present (PMN count >250/mm3) and thus whether
treatment is indicated. However, this is based on
a single-centre observational cohort study126 and
has not been addressed prospectively. Until then we
think that considering the lack of symptoms in
a large number of cirrhotic patients even in pres-
ence of severe bacterial infection antibiotic treat-
ment should be used in case of bacterascites.
Use of albumin as adjuvant treatment
In patients with cirrhosis with SBP, a prospective
randomised comparative study reported that adju-
vant administration of high-dose albumin (1.5 g/kg
on day 1 and 1 g/kg on day 3) with antibiotic
treatment prevented worsening of renal function
with a concomitant improvement in in-hospital
and 3-month survival.108 However, this regimen is
mainly effective in high-risk patients characterised
by serum bilirubin >4 mg/dl. In addition, in unse-
lected patients with SBP, even low-dose albumin
(10 g/day on days 1e3) has been shown to reduce
tumour necrosis factor and interleukin 6 levels in
serum and ascites and to prevent increases in serum
NOx induced by SBP.110 Therefore, future trials
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cirrhosis could also benefit and to establish the dose
and timing of albumin needed to give most benefit
to the individual patient.
Duration of treatment and control of treatment
success
Antibiotic treatment can safely be discontinued
after the ascites PMN count has decreased to <250/
mm3. In a comparative study, extension of treat-
ment duration to 10 days was not superior to
treatment for 5 days,127 and it is therefore recom-
mended that antibiotic therapy should be given for
5 days only. Moreover, current guidelines recom-
mend changing treatment if the PMN count does
not decrease by at least 25% compared with the
pretreatment level after 2 days of antibiotic treat-
ment.2 3 However, this has not been established in
a prospective manner and/or treatment algorithm.
In fact, this is based on a retrospective analysis
of the half-life of PMN in ascites after initiation
of antibiotic treatment128 and the observation
that the reduction in the ascites PMN count 48 h
after initiation of antibiotic treatment is greater
in survivors than in non-survivors (9269% vs
66638%).129 There is therefore a clear need to
establish the best time point and degree of
reduction in PMN count to exclude accurately
the chance of treatment failure in patients with
SBP.
PREVENTION OF SBP
Secondary and primary prophylaxis
The efficacy and role of prophylactic antibiotics is
indisputable in the setting of gastrointestinal
bleeding and in patients who recover from an
episode of SBP.1e4 For secondary prophylaxis, the
evidence is strongest for norfloxacin.130 Some
guidelines recommend the use of oral ciprofloxacin
(750 mg once weekly)1 or trimethoprim/sulfame-
thoxazole as an alternative.1 3 However, the use of
intermittent ciprofloxacin has been associated with
Figure 2 Meta-analysis of available data on the impact of multiresistant bacteria on mortality in cirrhosis.
Figure 3 Key elements driving development of bacterial
resistance and risk of treatment failure.
Box 2
Key messages established unequivocally
< Empirical antibiotic therapy must be initiated
immediately after the diagnosis of SBP is made.
< Uncomplicated community-acquired first SBP
can be treated orally with quinolones in
countries with low level quinolone resistance
rates, otherwise third-generation cephalosporins
should be used.
Controversial but proposed
< The choice of antibiotic regimen strongly needs
to consider (a) the site of acquisition (commu-
nity-acquired vs nosocomial), (b) prior antibiotic
treatment and (c) local resistance profile. In
cases of nosocomial SBP and either prior
hospitalisation with antibiotic treatement or
long-term antibiotic prophylaxis, the use of
carbapenems is recommended.
< Albumin should be used as adjuvant treatment
in patients with SBP and a high risk of
worsening renal function.
Questions to be addressed in the future
< What are the individual risk factors for SBP due
to multiresistant bacteria?
< Can asymptomatic bacterascites be left
untreated?
< In which patients and with what schedule (dose
and timing) should albumin be used as adjuvant
treatment to optimise benefit?
< What change in PMN count in the ascitic fluid
during antibiotic treatment defines best treat-
ment failure and therefore the need to alter
antibiotic treatment?
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a higher rate of quinolone-resistant organisms131
and, in our view, should therefore be avoided. Data
supporting the use of trimethoprim/sulfamethox-
azole are weak,132 while its side effects are poten-
tially dangerous and probably under-reported.133
Moreover, resistance to this class of antibiotics has
increased to a degree that it is no longer recom-
mended as the first-line choice for the empirical
treatment of urinary tract infections in some
countries.134 In patients with cirrhosis with
gastrointestinal haemorrhage, quinolones are most
frequently used and have been found to decrease
the incidence of severe infections (SBP and/or
septicaemia) and mortality. However, in patients
with bleeding necessitating invasive procedures,
infections are increasingly caused by Gram-positive
bacteria and intravenous delivery may be more
appropriate than the oral route. In fact, the third-
generation cephalosporin ceftriaxone administered
intravenously has been shown to be superior to oral
norfloxacin in patients with advanced cirrhosis
(ie, with at least two of the following: ascites,
severe malnutrition, encephalopathy or bilirubin
>3 mg/dl).135
With regard to the use of antibiotics for primary
prophylaxis in the setting of low protein ascites
(<1.5 mg/dl), eight randomised controlled trials
have been performed so far and are summarised in
table 2. However, four trials also included patients
with prior SBP132 139 142 143 and the remaining
have recently been summarised in two meta-anal-
yses.136 137 Surprisingly, these came to different
conclusions, most likely due to erroneous data
extraction.144 The study by Novella et al included
a large number of patients with gastrointestinal
bleeding,51 so only three trials truly focused on
primary prophylaxis.140 145 146 Here we present
a meta-analysis of these three studies, which
supports the efficacy of quinolones in the primary
prevention of SBP (figure 4).140 145 146 Corre-
sponding numbers needed to treat (NNT) at
6 months to prevent one episode of SBP or death are
8.4 and 8.6, respectively. Even limiting the data to
the two most recent and highest quality trials with
follow-up for 12 months140 145 demonstrates
significant preventive power for both end points:
SBP (NNT 6.3) and mortality (NNT 7.3). Despite
this evidence, most expert panels do not recom-
mend the routine use of antibiotics in every patient
with low protein ascites unless additional risk
factors are present.1 3 4 This is based on the fear of
accelerating selection of resistant bacteria by long-
term use of broad-spectrum antibiotics119 and the
lack of conclusive data supporting this approach.
Indeed, primary prophylaxis in patients with low
protein ascites without additional risk factors failed
to reach statistical significance in preventing SBP,
although reducing mortality was not calculated for
this end point.140 In contrast, Fernandez et al
further selected patients from the cohort with low
protein ascites by the presence of one of the
following criteria: (1) severe liver insufficiency,
defined as Child score $9 and serum bilirubin
$3 mg/dl; or (2) renal dysfunction defined as serum
creatinine $1.2 mg/dl, serum BUN $25 mg/dl or
serum sodium #130 mEq/l.145 In this highly
selected ‘high-risk’ group of patients with cirrhosis,
norfloxacin reduced the 1-year probability of SBP
from 61% to 7% (p<0.001) and improved the 1-year
survival probability from 48% to 60% (p<0.05).
Figure 4 Meta-analysis of randomised controlled trials of primary prophylaxis for spontanous bacterial peritonitis (12 months follow-up).
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Nonetheless, guidelines state very cautiously that
the long-term use of norfloxacin can be justified4 or
should be considered in these selected patients.1 3
However, since this trial fulfils the highest quality
criteria (Jadad score 5) and represents a well-defined
group of patients, we consider the use of norflox-
acin for primary prophylaxis as a standard of care
procedure.
Limitations in antibiotic prophylaxis and
alternatives
The longer the duration of antibiotic treatment, the
greater is the risk for selection of resistant strains
and the lower is the chance of reducing the inci-
dence of SBP. In fact, survival advantage using
norfloxacin as primary prophylaxis in highly
selected patients is most marked during the first
3 months of treatment (94% vs 62%, p¼0.003) and
decreases over time.138 145 We therefore propose
that the use of norfloxacin for primary prophylaxis
should also be considered in unselected patients
with low protein ascites if liver transplantation is
a realistic option within a few months. Although
there are no long-term data, the same time course
of antibiotic efficacy is likely to be present as in
secondary prophylaxis. Its use is recommended to
be continued until liver transplantation or until the
disappearance of ascites (eg, in alcoholics stopping
alcohol ingestion).2 3 In any other case, antibiotic
treatment guidelines support long-term use but, in
our view, improvement in liver disease should lead
to interruption of treatment.
Overall, the continuous use of a single antibiotic
appears not to be the optimal solution and efforts
should be made to seek alternatives which could
include antibiotic cycling. The basic principle of
cycling antibiotics is that bacteria acquiring resis-
tance to the first course of treatment would remain
susceptible to the second regimen, and so on. In
this context, future trials should test the use of
rifaximin since (a) it belongs to a different antibi-
otic class from the antibiotics tested prospectively
so far; (b) it exerts a broad range of antimicrobial
activity including Gram-positive bacteria141; (c) it
appears to cause considerably less bacterial resis-
tance147 148; and (d) it acts predominantly in the
small intestine,147e149 the site of bacterial over-
growth in cirrhosis. Finally, as has been pointed out
by others,150 151 effective non-antibiotic approaches
in reducing the incidence of SBP represent the Holy
Grail. Interestingly, a significant decrease in the
incidence of postoperative infections has been
reported in a cohort study of patients with cirrhosis
treated with propranolol and ciprofloxacin
compared with ciprofloxacin alone after laparo-
scopic surgery.152 Moreover, NSBB have been
reported to ameliorate pathological BT in experi-
mental cirrhosis.153 Finally, recent meta-analyses of
available data indicate that NSBB lower the risk of
SBP in patients with cirrhosis which may occur
independently of the haemodynamic response
achieved.65 66 However, the use of NSBB in patients
with refractory ascites has been suggested to
worsen prognosis154 155 and to be associated with
haemodynamic adverse effects after large-volume
paracentesis.156 Future prospective trials therefore
need to address these questions in detail in order to
establish the use of NSBB in the right patient at the
right time.
Cisapride, a serotonin 5-HT4 receptor agonist
and intestinal prokinetic drug, has been shown
to decrease SIBO and BT in experimental
cirrhosis41 157 but was abandoned due to cardiac
side effects. Nonetheless, these encouraging results
should stimulate human prospective trials investi-
gating other prokinetics such as the new highly
selective 5-HT4 receptor agonist prucalopride which
showed no interaction at other receptor sites.158
Other promising approaches reported to amelio-
rate BT in experimental cirrhosis include orally
administered conjugated bile acids, chol-
ylsarcosine,159 insulin-like growth factor I)160 and
anti-tumour necrosis factor.161 Probiotics have been
reported to correct bacterial overgrowth, stabilise
mucosal barrier function, improve neutrophil
function and decrease BT in experimental liver
failure.162 163 In patients with cirrhosis, symbiotic
treatment significantly reduced endotoxin levels
and improved the Child-Pugh functional class in
nearly 50% of cases.164 Similarly, the addition of
fibre to lactobacilli decreased postoperative bacterial
infections after liver transplantation.165 Probiotics
may even be helpful in limiting the development of
bacterial resistance, and trials are ongoing to
investigate their efficacy in eradicating carba-
penem-resistant bacteria as well as the decolonisa-
tion of MRSA in carrier patients (NCT00722410/
NCT00941356).
Box 3
Key messages: established unequivocally
< In patients with gastrointestinal haemorrhage,
antibiotic prophylaxis is mandatory using third-
generation cephalosporins (eg, ceftriaxone) in
severe liver disease or quinolones in less severe
and uncomplicated cases.
< Secondary prophylaxis is recommended after
resolution of SBP with the strongest evidence
supporting use of norfloxacin.
Controversial but proposed
< Primary prophylaxis can be justified in patients
with low protein ascites (<1.5 g/dl) and should
be used in the presence of severe liver disease
or renal impairment.
< Regimens applying antibiotics intermittently (eg,
once a week) should be avoided.
Questions to be addressed in the future
< Strong efforts should focus on effective prophy-
lactic measures with low or zero risk for
development of bacterial resistance including
use of: (a) antibiotic cycling; (b) rifaximin; or (c)
non-antibiotic treatments (eg, NSBB, proki-
netics, probiotics, bile acids).
306 Gut 2012;61:297e310. doi:10.1136/gutjnl-2011-300779
Recent advances in clinical practice
group.bmj.com on November 26, 2014 - Published by http://gut.bmj.com/Downloaded from 
Acknowledgements The authors thank Professor Thomas Glueck
(Hospital Trostberg, Germany) for helpful discussions, scientific
advice and for reviewing the manuscript.
Competing interests None.
Contributors RW and AG wrote the manuscript. AK performed the
statistical analysis and meta-analysis.
Provenance and peer review Commissioned; externally peer
reviewed.
REFERENCES
1. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of
spontaneous bacterial peritonitis delays hepatorenal syndrome
and improves survival in cirrhosis. Gastroenterology
2007;133:818e24.
2. Grange JD, Roulot D, Pelletier G, et al. Norfloxacin primary
prophylaxis of bacterial infections in cirrhotic patients with
ascites: a double-blind randomized trial [see comments]. J
Hepatol 1998;29:430e6.
3. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary
prophylaxis of spontaneous bacterial peritonitis: a randomized,
placebo-controlled study. J Hepatol 2008;48:774e9.
4. Runyon BA. Management of adult patients with ascites due to
cirrhosis: an update. Hepatology 2009;49:2087e107.
5. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in
cirrhosis: epidemiological changes with invasive procedures and
norfloxacin prophylaxis. Hepatology 2002;35:140e8.
6. Caly WR, Strauss E. A prospective study of bacterial infections
in patients with cirrhosis. J Hepatol 1993;18:353e8.
7. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial
peritonitis: a prospective investigation in predominantly
nonalcoholic cirrhotic patients. Hepatology 1983;3:545e9.
8. Evans LT, Kim WR, Poterucha JJ, et al. Spontaneous bacterial
peritonitis in asymptomatic outpatients with cirrhotic ascites.
Hepatology 2003;37:897e901.
9. Castellote J, Girbau A, Maisterra S, et al. Spontaneous bacterial
peritonitis and bacterascites prevalence in asymptomatic cirrhotic
outpatients undergoing large-volume paracentesis. J
Gastroenterol Hepatol 2008;23:256e9.
10. Jeffries MA, Stern MA, Gunaratnam NT, et al. Unsuspected
infection is infrequent in asymptomatic outpatients with
refractory ascites undergoing therapeutic paracentesis. Am J
Gastroenterol 1999;94:2972e6.
11. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in
cirrhosis: variations on a theme. Medicine (Baltimore)
1971;50:161e97.
12. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment
and prophylaxis of spontaneous bacterial peritonitis: a consensus
document. International Ascites Club. J Hepatol
2000;32:142e53.
13. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic
significance of bacterascites in cirrhosis with ascites. Dig Dis Sci
1995;40:561e5.
14. Follo A, Llovet JM, Navasa M, et al. Renal impairment after
spontaneous bacterial peritonitis in cirrhosis: incidence, clinical
course, predictive factors and prognosis. Hepatology
1994;20:1495e501.
15. Nobre SR, Cabral JE, Gomes JJ, et al. In-hospital mortality in
spontaneous bacterial peritonitis: a new predictive model. Eur J
Gastroenterol Hepatol 2008;20:1176e81.
16. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial
peritonitisein-hospital mortality, predictors of survival, and health
care costs from 1988 to 1998. Am J Gastroenterol
2001;96:1232e6.
17. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous
bacterial peritonitis in cirrhosis: frequency and predictive factors.
Hepatology 1988;8:27e31.
18. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial
peritonitis in cirrhosis: predictive factors of infection resolution
and survival in patients treated with cefotaxime. Hepatology
1993;17:251e7.
19. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for
spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Gastroenterol 1993;104:1133e8.
20. Silvain C, Besson I, Ingrand P, et al. Prognosis and long-term
recurrence of spontaneous bacterial peritonitis in cirrhosis. J
Hepatol 1993;19:188e9.
21. Terg R, Levi D, Lopez P, et al. Analysis of clinical course and
prognosis of culture-positive spontaneous bacterial peritonitis and
neutrocytic ascites. Evidence of the same disease. Dig Dis Sci
1992;37:1499e504.
22. Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with
cirrhosis increase mortality four-fold and should be used in
determining prognosis. Gastroenterology 2010;139:1246e56,
1256.e1e5.
23. Altman C, Grange JD, Amiot X, et al. Survival after a first
episode of spontaneous bacterial peritonitis. Prognosis of
potential candidates for orthotopic liver transplantation. J
Gastroenterol Hepatol 1995;10:47e50.
24. Cheong HS, Kang CI, Lee JA, et al. Clinical significance and
outcome of nosocomial acquisition of spontaneous bacterial
peritonitis in patients with liver cirrhosis. Clin Infect Dis
2009;48:1230e6.
25. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in
cirrhosis. Incidence, diagnosis, and prognosis. Scand J
Gastroenterol 1987;22:295e300.
26. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin
predict renal failure and mortality in patients with spontaneous
bacterial peritonitis: a retrospective study. Liver Int
2009;29:415e19.
27. Franca AV, De Souza JB, Silva CM, et al. Long-term prognosis
of cirrhosis after spontaneous bacterial peritonitis treated with
ceftriaxone. J Clin Gastroenterol 2001;33:295e8.
28. Kamani L, Mumtaz K, Ahmed US, et al. Outcomes in culture
positive and culture negative ascitic fluid infection in patients
with viral cirrhosis: cohort study. BMC Gastroenterol 2008;8:59.
29. Umgelter A, Reindl W, Miedaner M, et al. Failure of current
antibiotic first-line regimens and mortality in hospitalized patients
with spontaneous bacterial peritonitis. Infection 2009;37:2e8.
30. Cho JH, Park KH, Kim SH, et al. Bacteremia is a prognostic
factor for poor outcome in spontaneous bacterial peritonitis.
Scand J Infect Dis 2007;39:697e702.
31. Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotide-
binding oligomerization domain containing 2 (NOD2) variants are
genetic risk factors for death and spontaneous bacterial
peritonitis in liver cirrhosis. Hepatology 2010;51:1327e33.
32. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis.
Hepatology 2005;41:422e33.
33. Wiest R. Role of bacterial infections for hepatorenal syndrome.
In: Gerbes A, ed. Frontiers in Gastrointestinal Research. Aszites,
Hyponatremia and heptorenal syndrome. Basel, Switzerland:
Krager, 2010.
34. Wells CL. Relationship between intestinal microecology and the
translocation of intestinal bacteria. Antonie Van Leeuwenhoek
1990;58:87e93.
35. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The
detection of bacterial DNA in blood of rats with CCl4-induced
cirrhosis with ascites represents episodes of bacterial
translocation. Hepatology 2006;44:633e9.
36. Llovet JM, Bartoli R, March F, et al. Translocated intestinal
bacteria cause spontaneous bacterial peritonitis in cirrhotic
rats: molecular epidemiologic evidence. J Hepatol
1998;28:307e13.
37. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial
communities in patients with liver cirrhosis. Hepatology
2011;54:562e72.
38. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated
with a mouse model of alcoholic liver disease. Hepatology
2011;53:96e105.
39. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal
bacterial overgrowth in patients with cirrhosis: prevalence and
relation with spontaneous bacterial peritonitis. Am J
Gastroenterol 2001;96:2962e7.
40. Guarner C, Runyon BA, Young S, et al. Intestinal bacterial
overgrowth and bacterial translocation in cirrhotic rats with
ascites. J Hepatol 1997;26:1372e8.
41. Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on
intestinal bacterial overgrowth and bacterial translocation in
cirrhosis. Hepatology 2000;31:858e63.
41a. Teltschik Z, Wiest R, Beisner J, et al. Intestinal bacterial
translocation in cirrhotic rats is related to compromised Paneth
cell antimicrobial host defence. Hepatology (in press).
42. Chiva M, Guarner C, Peralta C, et al. Intestinal mucosal oxidative
damage and bacterial translocation in cirrhotic rats. Eur J
Gastroenterol Hepatol 2003;15:145e50.
43. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal
alterations in experimental cirrhosis in the rat: role of oxygen free
radicals. Hepatology 2002;35:622e9.
44. Dunn DL, Barke RA, Ahrenholz DH, et al. The adjuvant effect of
peritoneal fluid in experimental peritonitis. Mechanism and clinical
implications. Ann Surg 1984;199:37e43.
Gut 2012;61:297e310. doi:10.1136/gutjnl-2011-300779 307
Recent advances in clinical practice
group.bmj.com on November 26, 2014 - Published by http://gut.bmj.com/Downloaded from 
45. Gabele E, Muhlbauer M, Paulo H, et al. Analysis of monocyte
chemotactic protein-1 gene polymorphism in patients with
spontaneous bacterial peritonitis. World J Gastroenterol
2009;15:5558e62.
46. Joyce LD, Hau T, Hoffman R, et al. Evaluation of the mechanism
of zymosan-induced resistance to experimental peritonitis.
Surgery 1978;83:717e25.
47. Runyon BA, Morrissey RL, Hoefs JC, et al. Opsonic activity of
human ascitic fluid: a potentially important protective mechanism
against spontaneous bacterial peritonitis. Hepatology
1985;5:634e7.
48. Such J, Guarner C, Enriquez J, et al. Low C3 in cirrhotic ascites
predisposes to spontaneous bacterial peritonitis. J Hepatol
1988;6:80e4.
49. Runyon BA. Low-protein-concentration ascitic fluid is
predisposed to spontaneous bacterial peritonitis. Gastroenterol
1986;91:1343e6.
50. Llach J, Rimola A, Navasa M, et al. Incidence and predictive
factors of first episode of spontaneous bacterial peritonitis in
cirrhosis with ascites: relevance of ascitic fluid protein
concentration. Hepatology 1992;16:724e7.
51. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient
prophylaxis of the first episode of spontaneous bacterial
peritonitis with norfloxacin. Hepatology 1997;25:532e6.
52. Wiest R, Leidl F, Kopp A, et al. Peritoneal fluid adipokines: ready
for prime time? Eur J Clin Invest 2009;39:219e29.
53. Guarner C, Sola R, Soriano G, et al. Risk of a first community-
acquired spontaneous bacterial peritonitis in cirrhotics with
low ascitic fluid protein levels. Gastroenterology
1999;117:414e19.
54. Obstein KL, Campbell MS, Reddy KR, et al. Association between
model for end-stage liver disease and spontaneous bacterial
peritonitis. Am J Gastroenterol 2007;102:2732e6.
55. Riordan SM, Skinner N, Nagree A, et al. Peripheral blood
mononuclear cell expression of toll-like receptors and relation to
cytokine levels in cirrhosis. Hepatology 2003;37:1154e64.
56. Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on
chronic liver failure display “sepsis-like” immune paralysis. J
Hepatol 2005;42:195e201.
57. Berres ML, Schnyder B, Yagmur E, et al. Longitudinal monocyte
human leukocyte antigen-DR expression is a prognostic marker in
critically ill patients with decompensated liver cirrhosis. Liver Int
2009;29:536e43.
58. Hassner A, Kletter Y, Jedvab M, et al. Impaired monocyte
function in liver cirrhosis. Lancet 1979;1:329e30.
59. Rajkovic IA, Williams R. Abnormalities of neutrophil
phagocytosis, intracellular killing and metabolic activity in
alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252e62.
60. Bruns T, Peter J, Reuken PA, et al. NOD2 gene variants are
a risk factor for culture-positive spontaneous bacterial peritonitis
and monomicrobial bacterascites in cirrhosis. Liver Int
2011:10e3231.
61. Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor
(TLR) 2 promotor and intron 2 polymorphisms are associated with
increased risk for spontaneous bacterial peritonitis in liver
cirrhosis. J Hepatol 2011;55:1010e16.
62. Netea MG, Ferwerda G, de Jong DJ, et al. Nucleotide-binding
oligomerization domain-2 modulates specific TLR pathways for
the induction of cytokine release. J Immunol 2005;174:6518e23.
63. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of
proton pump inhibitor therapy with spontaneous bacterial
peritonitis in cirrhotic patients with ascites. Am J Gastroenterol
2009;104:1130e4.
64. Trikudanathan G, Israel J, Cappa J, et al. Association between
proton pump inhibitors and spontaneous bacterial peritonitis in
cirrhotic patientsda systematic review and meta-analysis. Int J
Clin Pract 2011;65:674e8.
65. Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect
against spontaneous bacterial peritonitis in cirrhotic patients:
a meta-analysis. Liver Int 2009;29:1189e93.
66. Krag A, Wiest R, Albillos A, et al. Reduced mortality with non-
selective betablockers (NSBB) compared to banding is not
related to prevention of bleeding or bleeding related mortality:
a hypothesis for non-hemodynamic effects of NSBB. J Hepatol
2011;54:S72.
67. Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic
receptor, and immunity. Brain Behav Immun 2002;16:290e332.
68. Worlicek M, Knebel K, Linde HJ, et al. Splanchnic
sympathectomy prevents translocation and spreading of E coli
but not S aureus in liver cirrhosis. Gut 2010;59:1127e34.
69. Chinnock B, Afarian H, Minnigan H, et al. Physician clinical
impression does not rule out spontaneous bacterial peritonitis in
patients undergoing emergency department paracentesis. Ann
Emerg Med 2008;52:268e73.
70. Hoefs JC. Increase in ascites white blood cell and protein
concentrations during diuresis in patients with chronic liver
disease. Hepatology 1981;1:249e54.
71. Albillos A, Cuervas-Mons V, Millan I, et al. Ascitic fluid
polymorphonuclear cell count and serum to ascites albumin
gradient in the diagnosis of bacterial peritonitis. Gastroenterology
1990;98:134e40.
72. Garcia-Tsao G, Conn HO, Lerner E. The diagnosis of bacterial
peritonitis: comparison of pH, lactate concentration and leukocyte
count. Hepatology 1985;5:91e6.
73. Stassen WN, McCullough AJ, Bacon BR, et al. Immediate
diagnostic criteria for bacterial infection of ascitic fluid. Evaluation
of ascitic fluid polymorphonuclear leukocyte count, pH, and
lactate concentration, alone and in combination. Gastroenterology
1986;90:1247e54.
74. Yang CY, Liaw YF, Chu CM, et al. White count, pH and lactate in
ascites in the diagnosis of spontaneous bacterial peritonitis.
Hepatology 1985;5:85e90.
75. Campillo B, Richardet JP, Kheo T, et al. Nosocomial
spontaneous bacterial peritonitis and bacteremia in cirrhotic
patients: impact of isolate type on prognosis and characteristics
of infection. Clin Infect Dis 2002;35:1e10.
76. Gonzalez-Navajas JM, Bellot P, Frances R, et al. Presence of
bacterial-DNA in cirrhosis identifies a subgroup of patients with
marked inflammatory response not related to endotoxin. J
Hepatol 2008;48:61e7.
77. Angeloni S, Nicolini G, Merli M, et al. Validation of automated
blood cell counter for the determination of polymorphonuclear cell
count in the ascitic fluid of cirrhotic patients with or without
spontaneous bacterial peritonitis. Am J Gastroenterol
2003;98:1844e8.
78. Riggio O, Angeloni S, Parente A, et al. Accuracy of the
automated cell counters for management of spontaneous
bacterial peritonitis. World J Gastroenterol 2008;14:5689e94.
79. Cereto F, Genesca J, Segura R. Validation of automated blood
cell counters for the diagnosis of spontaneous bacterial
peritonitis. Am J Gastroenterol 2004;99:1400.
80. Nousbaum JB, Cadranel JF, Nahon P, et al. Diagnostic accuracy
of the Multistix 8 SG reagent strip in diagnosis of spontaneous
bacterial peritonitis. Hepatology 2007;45:1275e81.
81. Hiscoke C, Yoxall H, Greig D, et al. Validation of a method for the
rapid diagnosis of urinary tract infection suitable for use in general
practice. Br J Gen Pract 1990;40:403e5.
82. Mendler MH, Agarwal A, Trimzi M, et al. A new highly sensitive
point of care screen for spontaneous bacterial peritonitis using
the leukocyte esterase method. J Hepatol 2010;53:477e83.
83. Bruns T, Sachse S, Straube E, et al. Identification of bacterial
DNA in neutrocytic and non-neutrocytic cirrhotic ascites by
means of a multiplex polymerase chain reaction. Liver Int
2009;29:1206e14.
84. Frances R, Benlloch S, Zapater P, et al. A sequential study of
serum bacterial DNA in patients with advanced cirrhosis and
ascites. Hepatology 2004;39:484e91.
85. Frances R, Zapater P, Gonzalez-Navajas JM, et al. Bacterial
DNA in patients with cirrhosis and noninfected ascites mimics
the soluble immune response established in patients with
spontaneous bacterial peritonitis. Hepatology 2008;47:978e85.
86. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and
ascitic fluid bacterial DNA: a new independent prognostic factor
in noninfected patients with cirrhosis. Hepatology
2008;48:1924e31.
87. Chinnock B, Fox C, Hendey GW. Gram’s stain of peritoneal fluid
is rarely helpful in the evaluation of the ascites patient. Ann
Emerg Med 2009;54:78e82.
88. Conn HO. Unusual presentations of SBP. In: Conn HO, Rodes J,
Navasa M, eds. London: Informa Healthcare, 2000:47e74.
89. Ortiz J, Soriano G, Coll P, et al. Early microbiologic diagnosis of
spontaneous bacterial peritonitis with BacT/ALERT. J Hepatol
1997;26:839e44.
90. Siersema PD, de Marie S, van Zeijl JH, et al. Blood culture
bottles are superior to lysis-centrifugation tubes for
bacteriological diagnosis of spontaneous bacterial peritonitis. J
Clin Microbiol 1992;30:667e9.
91. Castellote J, Xiol X, Verdaguer R, et al. Comparison of two
ascitic fluid culture methods in cirrhotic patients with
spontaneous bacterial peritonitis. Am J Gastroenterol
1990;85:1605e8.
92. Klaerner HG, Eschenbach U, Kamereck K, et al. Failure of an
automated blood culture system to detect nonfermentative gram-
negative bacteria. J Clin Microbiol 2000;38:1036e41.
308 Gut 2012;61:297e310. doi:10.1136/gutjnl-2011-300779
Recent advances in clinical practice
group.bmj.com on November 26, 2014 - Published by http://gut.bmj.com/Downloaded from 
93. Pelletier G, Salmon D, Ink O, et al. Culture-negative neutrocytic
ascites: a less severe variant of spontaneous bacterial peritonitis.
J Hepatol 1990;10:327e31.
94. Gerbes AL, Jungst D, Xie YN, et al. Ascitic fluid analysis for
the differentiation of malignancy-related and nonmalignant
ascites. Proposal of a diagnostic sequence. Cancer
1991;68:1808e14.
95. Wang SS, Lu CW, Chao Y, et al. Malignancy-related ascites:
a diagnostic pitfall of spontaneous bacterial peritonitis by ascitic
fluid polymorphonuclear cell count. J Hepatol 1994;20:79e84.
96. Casafont F, Rivero M, Fernandez MD, et al. Granulocyte elastase
in cirrhotic patients with spontaneous bacterial peritonitis. Dig Dis
Sci 1999;44:1985e9.
97. Parsi MA, Saadeh SN, Zein NN, et al. Ascitic fluid lactoferrin for
diagnosis of spontaneous bacterial peritonitis. Gastroenterology
2008;135:803e7.
98. Soriano G, Castellote J, Alvarez CE, et al. Secondary bacterial
peritonitis in cirrhosis: a retrospective study of clinical and
analytical characteristics, diagnosis and management. J Hepatol
2009;52:39e44.
99. Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation
of spontaneous bacterial peritonitis from gastrointestinal tract
perforation into ascitic fluid. Hepatology 1984;4:447e50.
100. Wu SS, Lin OS, Chen YY, et al. Ascitic fluid carcinoembryonic
antigen and alkaline phosphatase levels for the differentiation of
primary from secondary bacterial peritonitis with intestinal
perforation. J Hepatol 2001;34:215e21.
101. Wiest R, Schoelmerich J. Secondary peritonitis in cirrhosis: “Oil
in fire”. J Hepatol 2009;52:7e9.
102. Song KH, Jeon JH, Park WB, et al. Clinical outcomes of
spontaneous bacterial peritonitis due to extended-spectrum beta-
lactamase-producing Escherichia coli and Klebsiella species:
a retrospective matched case-control study. BMC Infect Dis
2009;9:41.
103. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk
for health care-associated bacterial infections. Clin Gastroenterol
Hepatol 2010;8:979e85.
104. Kresken M, Hafner D, Schmitz FJ, et al. Resistenzsituation bei
klinisch wichtigen Infektionserregern gegenüber Antibiotika in
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in situ hybridisation, the authors found
bacteria deeply infiltrating the appendix.
Fusobacteria (mainly Fusobacterium nucle-
atum/necrophorum) were specific components
of epithelial and submucosal infiltrates in
62% of patients and were not found in
various controls. The presence of Fusobac-
teria correlated positively with the severity
of appendicitis. Conversely, main faecal
microbiota including Faecalibacterium praus-
nitzii groups were significantly decreased
with an inverse relationship with the
severity of the disease.1
Altogether, these observations point to the
presence of a local appendiceal dysbiosis
with more bacteria with inflammatory
properties and fewer bacteria with anti-
inflammatory properties associated with
acute appendicitis. The genus Fusobacterium
is characterised by high proteolytic activity
and comprises different distinct species. The
most frequently encountered is F nucleatum,
which is frequent in the oral sphere and
implicated in periodontitis. F necrophorum has
a high pathogenic potential and is implicated
in life-threatening infections such as
Lemierre’s syndrome. In cattle, it is found in
footrot disease and is also frequent in liver
abscesses. The third important species is F
varium. All species are part of the normal
intestinal microflora. By contrast, F praus-
nitzii, which showed decreased numbers in
appendicitis, is a bacterium with anti-
inflammatory properties. Its numbers are
also reduced in patients with inflammatory
bowel disease and it is associated with
postoperative recurrence of Crohn’s disease.2
Over 30 studies have now analysed the
association between appendectomy and
ulcerative colitis (UC) and the majority of
the studies support a highly significant
inverse relationship.3 It is also well estab-
lished that the protective effect of appen-
dectomy depends on the inflammatory
conditions (appendicitis or lymphadenitis)
that were the indication for appendectomy
rather than on appendectomy itself.4 The
available data regarding whether or not
appendectomy performed after the onset of
UC can modulate its clinical course arey still
limited and conflicting and properly
controlled trials are needed.5 Despite accu-
mulating clinical evidence, the mechanism
linking appendicitis, appendectomy and UC
remains elusive.
Interestingly, a link between Fusobacteria
and UC has been reported in several studies.
In 2002, F varium was reported to be present
in the colonic mucosa of a high proportion
(84%) of UC patients.6 Using immunoblot-
ting with a F varium antigen Minami et al
found positive signals with sera from 45
(40.2%) of 112 UC patients versus 20
(15.6%) of 128 healthy controls (p<0.01).
Seropositive UC patients were more likely
to have clinically severe disease than sero-
negative UC patients and the disease loca-
tion in seropositive patients was more
extensive than in seronegative patients.7
Finally, a 2-week triple antibiotic therapy to
which F varium is susceptible (tetracycline,
metronidazole and amoxicillin) produced
improvement, remission and steroid with-
drawal in active UC more effectively than
a placebo.8
In conclusion, the development of an
appendiceal dysbiosis may be a priming
event in the occurrence of UC. The removal
of the appendix may reduce the risk of
further development of UC in genetically
susceptible individuals. We believe that this
hypothesis should be further explored in
studies examining the protective role of
appendicitis and appendectomy in UC.
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